Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells

Acute Myeloid Leukemia

(2017) Margaret R. O'Donnell et al.   Journal of the National Comprehensive Cancer Network

Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML

(2012) M.-C. Lo et al.   BLOOD

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

(2012) A. Eghtedar et al.   BLOOD

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

(2012) E Weisberg et al.   LEUKEMIA

Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

(2011) Nicolas Goardon et al.   CANCER CELL

Bone Marrow Stroma-Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor

(2011) T. Manshouri et al.   CANCER RESEARCH

Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia

(2011) Takayuki Ikezoe et al.   INTERNATIONAL JOURNAL OF CANCER

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

(2011) K C Goh et al.   LEUKEMIA

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

(2011) I Cristóbal et al.   LEUKEMIA

Stem cell gene expression programs influence clinical outcome in human leukemia

(2011) Kolja Eppert et al.   NATURE MEDICINE

Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia

(2010) Michael Heuser et al.   EXPERIMENTAL HEMATOLOGY

Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

(2010) Jean-Emmanuel Sarry et al.   JOURNAL OF CLINICAL INVESTIGATION

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes

(2009) Chunaram Choudhary et al.   MOLECULAR CELL

Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells

(2008) D. C. Taussig et al.   BLOOD

HOX expression patterns identify a common signature for favorable AML

(2008) M Andreeff et al.   LEUKEMIA